## Table SI. Tumour, nodes, metastases, blood (TNMB) classification (International Society for Cutaneous Lymphomas/European Organization of Research and Treatment of Cancer (ISCL/EORTC) revision (21)

TNMB classification		
Skin	T <sub>1</sub>	Patches <sup>1</sup> , papules and/or plaques <sup>2</sup> <10% of body surface ( $T_{1a}$ : Patch – $T_{1b}$ : Plaque +/- patch)
	T <sub>2</sub>	Patches, papules and/or plaques >10% of body surface ( $T_{22}$ : Patch – $T_{22}$ : Plaque +/– patch)
	T3	One or more tumours (>1 cm diameter)
	T <sub>4</sub>	Confluent erythema >80% of body surface
Node	No	No clinically abnormal peripheral lymph nodes
	N <sub>1</sub>	Clinically abnormal peripheral lymph nodes <sup>3</sup> ; histopathology Dutch grade 1 or NCI LN0-2. (N <sub>1a</sub> : clone-, N <sub>1b</sub> : clone+)
	N <sub>2</sub>	Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 2 or NCI LN3 ( $N_{2a}$ : clone-, $N_{2b}$ : clone +)
	N.3	Clinically abnormal peripheral lymph nodes; histopathology Dutch grades 3-4 or NCI LN4; clone+/-
Visceral	M	No visceral organs involved
	M <sub>1</sub>	Viscera involved (with pathological confirmation – imaging for spleen/liver)
Blood	B	<5% of peripheral blood lymphocytes are Sézary cells <sup>4</sup> ( $B_{ns}$ : clone – $B_{ns}$ : clone +)
	B <sub>1</sub>	>5% of peripheral blood lymphocytes are Sézary cells ( $B_{ia}$ : clone- $B_{ia}$ : clone +)
	B <sub>2</sub>	High tumour burden: ≥1,000/µl Sézary cells with clone +

<sup>1</sup>patches- not significantly elevated nor indurated skin lesions of any size; <sup>2</sup>plaques- elevated or indurated skin lesions of any size, <sup>3</sup>abnormal peripheral lymph nodes - firm, irregular, clustered, fixed or >= 1.5 cm in diameter lymph nodes. <sup>4</sup>Sezary cells – atypical lymphocytes with hyperconvoluted, cerebriform nuclei